News search

E.g., 02/06/2026
E.g., 02/06/2026
from left to right: Haruka Toda, Irene García Martín, María Maeve Soto Pérez, Alexia Ramos Gutiérrez, Mirian Nieto Delgado, Demetrio Julián Santiago Castillo, Paola Rocío Riveros Rodríguez, Lucía Pilar López Palomar, Andrés Redondo Rodríguez, Jorge García Quintanilla, Marinela Couselo Seijas, David Filgueiras Rama, and José Jalife.
Research
28 May 2026

The findings, published in Cardiovascular Research, show that the right ventricle has greater metabolic resilience than the left during cardiac arrest caused by ventricular fibrillation.

Annalaura Mastrangelo
Optimal dendritic-cell-based antitumor immunotherapy with cDC1 cells requires active mitochondria. Whereas vaccination with normal cDC1 cells efficiently reduces metastasis in B16-OVA tumors, the antitumor efficacy of these cells is diminished when their mitochondria are damaged.
Research
22 May 2026

CNIC-led study identifies a mitochondrial “checkpoint” that enables dendritic cells to efficiently activate T lymphocytes against viruses and tumors

Francesco Costa
Anthony Firulli
Job Verdonschot, Maastricht University Medical Center, and the Cardiovascular Research Institute Maastricht
Research
23 Apr 2026

Job Verdonschot, Maastricht University Medical Center, and the Cardiovascular Research Institute Maastricht

Dr. Pablo García-Pavía junto con la Dra. Noelia Mora y la Dra. Belén Peiró
Research
21 Apr 2026

The biomarker MR-proADM improves risk prediction in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and is associated with greater disease severity, mortality, and heart failure events.

David Sancho, Ignacio Heras-Murillo y Stefanie Wculek.
Research
15 Apr 2026

Scientist at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and the Institute for Research in Biomedicine (IRB Barcelona) uncover a key metabolic mechanism governing immune cell readiness

El Dr. David Sancho, junto a María Cid y Lola Manterola, de la Fundación Cris contra el Cáncer
About the CNIC
13 Apr 2026

TARGET-DC, CNIC initiative led by Dr. David Sancho aims to identify novel immune checkpoints in dendritic cells to advance T-cell activation.